Research Article
Efficacy and Safety of Hetrombopag for Thrombocytopenia in Patients with Advanced Solid Tumors: A Retrospective Study
Table 1
Analysis of characteristics of 60 patients with thrombocytopenia caused by antitumor therapy for malignant tumor (n, %).
| | General characteristics | Total (n = 60) |
| | Age/years (n, %) | | >60 years | 36 (60.0%) | | ≤60 years | 24 (40.0%) |
| | Gender (n, %) | | Male | 34 (56.7%) | | Female | 26 (43.3%) |
| | Primary tumor (n, %) | | Gastric cancer | 9 (15.0%) | | Gynecologic neoplasms (ovary/cervix) | 9 (15.0%) | | Pancreatic cancer | 8 (13.3%) | | Liver cancer | 7 (11.7%) | | Lung cancer | 7 (11.7%) | | Colorectal cancer | 6 (10.0%) | | Esophageal cancer | 4 (6.7%) | | Breast cancer | 4 (6.7%) | | Others | 6 (10.0%) |
| | ECOG score (n, %) | | 0 point | 49 (81.7%) | | 1 point | 11 (18.3%) |
| | Antitumor treatment regimen (n, %) | | Chemotherapy only | 13 (21.7%) | | Targeted/targeted + chemotherapy only | 12 (20.0%) | | Immune/immune + chemotherapy only | 17 (28.3%) | | Targeting + immunization/targeting + immunization + chemotherapy | 18 (30.0%) |
| | Platelet count distribution prior to hetrombopag use (n, %) | | 50 × 109/L–75 × 109/L (grade 2) | 37 (61.7%) | | 25 × 109/L–50 × 109/L (grade 3) | 17 (28.3%) | | <25 × 109/L (grade 4) | 6 (10.0%) |
| | Prior platelet increasing therapy (n, %) | | rhTPO | 36 (60.0%) | | TPO-RA (avatrapopag, eltrombopag) | 4 (6.7%) | | None | 20 (33.3%) |
| | Hetrombopag therapeutic dose (n, %) | | 2.5 mg | 11 (18.3%) | | 5 mg | 49 (81.7%) |
| | KPS score (n, %) | | 90 point | 60 (100.0%) |
|
|
ECOG, Eastern Cooperative Oncology Group; rhTPO, recombinant human thrombopoietin; TPO-RA; thrombopoietin receptor agonist; KPS; Karnofsky.
|
